The positive study results are likely to increase investor confidence in Viking Therapeutics' potential to successfully develop treatments for metabolic and endocrine disorders, particularly NASH. This optimism is reflected in the stock's price increase. The anticipation of further data in the first half of 2024 could maintain investor interest and potentially lead to further stock price appreciation in the short term.